Atlantic Bone Screen

Pre-clinical

Nantes, FranceFounded 2008atlantic-bone-screen.com

Atlantic Bone Screen operates as a preclinical CRO, historically expert in bone physiology, now offering a broad portfolio of validated models and analytical services across multiple therapeutic areas. The company positions itself as a reliable and responsive partner for biotechs, pharma, and academic sponsors, emphasizing scientific advice, customized protocols, and high-quality data interpretation. Its strategic direction involves expanding its service offerings and maintaining a strong focus on animal ethics and scientific expertise to support the global drug development pipeline.

Founded

2008

Focus

Rare DiseaseMetabolic

AI Company Overview

Technology Platform

Integrated preclinical service platform offering validated in vitro cell assays, in vivo animal models, and a comprehensive suite of ex vivo analytical services including specialized histology, histomorphometry, preclinical imaging, and biomarker analysis.

Opportunities

Growth is driven by increasing R&D in complex osteoarticular diseases, the expansion of regenerative medicine and biomaterials, and demand for specialized preclinical models in dermatology and oncology.

The company can leverage its deep histological expertise to become a partner of choice for advanced ex vivo analysis.

Risk Factors

Key risks include dependence on client R&D budgets, intense competition from larger CROs, regulatory changes affecting animal research, and potential operational challenges in maintaining consistent service quality across a growing portfolio.

Competitive Landscape

Competes with large global CROs (e.g., Charles River, Labcorp) and niche specialists. Differentiates through deep expertise in bone biology and histology, high-touch scientific collaboration, flexible protocol customization, and a strong emphasis on animal ethics and data interpretation quality.